Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects

NCT00540501 Phase 1 WITHDRAWN

This study is a 4 period study to see if there is any interaction between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 1
Status	WITHDRAWN
Start date	2007-10
Completion	2007-10

Conditions

• Healthy Subjects

Interventions

• Oseltamivir and Intravenous Zanamivir

Primary outcomes

• Oseltamivir carboxylate levels: Cmax and AUC(0-12)- — Period 2: Day 1, 2 & 3. Period 3: Day 1, 2 & 3. Period 4: Day 1, 2 & 3.